Novartis Sells 71% India Stake to ChrysCapital for ₹1,446 Cr

Introduction

Swiss drugmaker Novartis AG has announced the sale of its entire 70.68% stake in its publicly listed Indian arm, Novartis India Limited, to a consortium of investors led by private equity firm ChrysCapital. The transaction, valued at approximately ₹1,446 crore, marks a significant strategic shift for Novartis as it streamlines its global operations to focus on innovative medicines. The deal triggers a mandatory open offer for public shareholders and will result in a change of control and name for the Indian entity.

The Landmark Transaction

In a formal exchange filing, Novartis India confirmed that its promoter, Novartis AG, entered into a share purchase agreement on February 19, 2026. The agreement facilitates the sale of 1.74 crore fully paid-up equity shares to a consortium comprising WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. Upon the deal's completion, expected in the third quarter of 2026, Novartis AG will cease to be the promoter, and the ChrysCapital-led consortium will assume control.

A Differentiated Deal Structure

The acquisition involves a differentiated pricing structure for the various entities within the buying consortium. This approach highlights the complex financial engineering behind the transaction. The total consideration for the 70.68% stake amounts to ₹1,445.89 crore.

Mandatory Open Offer for Public Shareholders

As per SEBI regulations, the acquisition of a controlling stake triggers a mandatory open offer to public shareholders. The consortium has announced an offer to acquire an additional 26% stake, or up to 64.19 lakh equity shares, from the public. The open offer is priced at ₹860.64 per share, representing a 3.6% premium over the closing price on February 19, 2026. The total potential outlay for the open offer is approximately ₹552.49 crore.

Strategic Rationale for Novartis AG

This divestment is a direct result of a strategic review initiated by Novartis AG in February 2024. The move aligns with the company's global strategy to transform into a 'pure-play' innovative medicines company. By selling its stake in the listed Indian entity, Novartis AG is adapting its operational footprint to focus on sustainable long-term growth driven by its core research and development pipeline.

ChrysCapital's Major Pharma Acquisition

For ChrysCapital, this transaction marks its first majority stake acquisition in the Indian pharmaceutical sector, signaling a strong bullish outlook on the industry. The private equity firm has a history of successful investments in the space, including stakes in companies like Intas Pharma, Eris Lifesciences, Corona Remedies, and La Renon. This deal significantly strengthens its portfolio and establishes it as a controlling stakeholder in a well-established pharma business.

Impact on Novartis India

Following the completion of the transaction, Novartis India Limited will undergo significant changes. The company is required to change its name to remove all references to the Novartis group within 120 days. Furthermore, ChrysCapital will have the right to nominate directors to the board, effectively taking over management control. The company's business, which includes a portfolio of treatments for diabetes, neurological, cardiological, and dermatological conditions, including the well-known painkiller Voveran, will continue under the new ownership.

Novartis's Continued Presence in India

It is important to note that this sale does not mark a complete exit for Novartis from India. The company will maintain a significant presence through Novartis Healthcare Private Limited (NHPL), its wholly-owned subsidiary. NHPL houses the commercial arm, a corporate center in Hyderabad, and R&D teams conducting clinical trials at over 300 sites across the country. Novartis has stated it remains deeply committed to India, employing over 9,000 associates and continuing to expand its innovative portfolio in areas like Cardio Renal Metabolic and Oncology.

Financial Snapshot and Market Reaction

For the fiscal year 2024-25, Novartis India Limited reported revenues of ₹356.27 crore and a net profit of ₹100.90 crore. Ahead of the announcement, on February 19, 2026, the company's stock closed at ₹830.45 per share, with a market capitalization of ₹2,050.45 crore. The open offer price provides a modest premium to public shareholders.

Conclusion

The sale of Novartis AG's stake in its Indian arm is a strategic move that serves the objectives of both the seller and the buyer. For Novartis, it is a step towards becoming a more focused global innovator. For ChrysCapital, it is a landmark acquisition that deepens its footprint in the robust Indian pharmaceutical market. The transaction will now proceed through regulatory approvals and the open offer process, with a full transition of control expected later in the year.